Overview
Updated 14 Jul 2026
James H. Doroshow, MD, is Director, Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute. The public record shows 1,455 publications with 38,626 citations (h-index 97), centered on Cancer Genomics and Diagnostics, Radiomics and Machine Learning in Medical Imaging, Cancer therapeutics and mechanisms. It also documents an investigator role on 10 registered clinical trials, 1 NIH-funded awards (1999–2000).
- Most recent indexed publication: 2026 · Molecular cancer therapeutics
- Top research focus: Cancer Genomics and Diagnostics
- 10 registered trials on ClinicalTrials.gov
Generated from the cited public record · current as of 14 Jul 2026. Every fact links its source below.
Indications focusfrom trials led + research topics
Research focusOpenAlex concept fingerprint
Works withtrial sponsors and companies reporting payments
Scholarshipindexed output and impact (OpenAlex)
View publications ↓Distinct works indexed by OpenAlex, matched via ORCID; 36 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 428.
Clinical & industrytrials, payments and federal funding
Clinical trials
Updated 14 Jul 2026
Listed as an investigator on 10 registered studies on ClinicalTrials.gov. The most recent:
- 5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
Sponsor: National Cancer Institute (NCI)
InvestigatorPhase 1RecruitingNCT03366116 - Collection and Storage of Tissue and Blood Samples From Patients With Cancer
Sponsor: National Cancer Institute LAO
InvestigatorRecruitingNCT02474160 - Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors
Sponsor: National Cancer Institute (NCI)
InvestigatorPhase 1CompletedNCT02423057
Industry payments
No payments involving this person were reported to CMS in program years 2021–2024. Why? →
NIH funding
Updated 14 Jul 2026
1 NIH research award on record, funded 1999–2000 per NIH RePORTER. The latest:
- NADPH Oxidases as Novel Targets for Cancer Therapy
Division of Basic Sciences - Nci
FY2025$1,201,732ZIABC010677 - NADPH Oxidases as Novel Targets for Cancer Therapy
Division of Basic Sciences - Nci
FY2024$1,201,276ZIABC010677
Congress activity
Updated 14 Jul 2026
296 congress contributions (2004–2026) across AACR, ASCO, ASH per OpenAlex. The most recent:
- Abstract 4491: HDAC inhibitors induce NOX5 expression in human uveal melanoma cells in a Brd4-Sp1/Sp3-dependent manner.
AACR Annual Meeting
AACR2026Co-author - Abstract 6504: Combinatorial profiling of pidnarulex and other G-quadruplex ligands in 3D multicellular tumor spheroids
AACR Annual Meeting
AACR2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Jul 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Atezolizumab for Alveolar Soft Part Sarcoma: A Clinical Trial Update.
Journal of clinical oncology
2026 - Childhood cancer data initiative: expanded access to tumor molecular profiling for children, adolescents, and young adults.
Journal of the National Cancer Institute
2026
Most-cited worksby citation count (OpenAlex)
- 01Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors2,185 citations2012
- 02
- 03
- 04
- 05
Contact
An office address from a public listing. This research profile has no federal registry record to draw from.
Office address
Building 31, Room 3A44, Bethesda, MD 20892
Network
Updated 14 Jul 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 14 Jul 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Educationdegrees and training on record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.gov ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.gov ↗
Editorial & leadership rolesjournal and society appointments
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →irp.nih.gov ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →irp.nih.gov ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cancer.gov ↗
Secondary affiliationsappointments beyond the home institution
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.gov ↗
- Chairman
Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center
2004verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.gov ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →aacr.org ↗
Media & interviewspress, podcasts and appearances
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
- Author/contributor profile
OncLive (oncology news outlet)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Online presence
Updated 14 Jul 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Mentions by otherswhere others cite or feature them
- Facebook
m.facebook.com/story.php
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →m.facebook.com ↗ - Facebook
facebook.com/NCImedia/photos/dr-james-doroshow-deputy-director-the-nci-appeared-on-c-cpsans-washington-journal/10152788251470933
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →facebook.com ↗ - Instagram
instagram.com/p/C110-yNMMqP
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →instagram.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Pasi Janne, MD, PhD
Harvard University
- 2,385
- publications
- 163
- h-index
- 15
- trials
Julie Brahmer, MD
Bloomberg (United States)
- 855
- publications
- 116
- h-index
- 12
- trials
Enriqueta Felip, MD, PhD
Hebron University
- 1,460
- publications
- 129
- h-index
- 8
- trials
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center
- 2,643
- publications
- 148
- h-index
- 8
- trials